HomeCompareCAH vs SYK

CAH vs SYK: Dividend Comparison 2026

CAH yields 0.99% · SYK yields 1.04%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYK wins by $21.8K in total portfolio value
10 years
CAH
CAH
● Live price
0.99%
Share price
$206.31
Annual div
$2.04
5Y div CAGR
5.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.6K
Annual income
$185.04
Full CAH calculator →
SYK
SYK
● Live price
1.04%
Share price
$326.10
Annual div
$3.40
5Y div CAGR
46.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$8,282.98
Full SYK calculator →

Portfolio growth — CAH vs SYK

📍 SYK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAHSYK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAH + SYK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAH pays
SYK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAH
Annual income on $10K today (after 15% tax)
$83.95/yr
After 10yr DRIP, annual income (after tax)
$157.28/yr
SYK
Annual income on $10K today (after 15% tax)
$88.62/yr
After 10yr DRIP, annual income (after tax)
$7,040.53/yr
At 15% tax rate, SYK beats the other by $6,883.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAH + SYK for your $10,000?

CAH: 50%SYK: 50%
100% SYK50/50100% CAH
Portfolio after 10yr
$32.4K
Annual income
$4,234.01/yr
Blended yield
13.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYK right now

CAH
Analyst Ratings
18
Buy
15
Hold
Consensus: Buy
Price Target
$252.33
+22.3% upside vs current
Range: $220.00 — $275.00
Altman Z
4.8
Piotroski
5/9
SYK
Analyst Ratings
1
Strong
35
Buy
14
Hold
Consensus: Buy
Price Target
$428.67
+31.5% upside vs current
Range: $390.00 — $469.00
Altman Z
4.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAH buys
0
SYK buys
0
No recent congressional trades found for CAH or SYK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAHSYK
Forward yield0.99%1.04%
Annual dividend / share$2.04$3.40
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.6%46.2%
Portfolio after 10y$21.6K$43.3K
Annual income after 10y$185.04$8,282.98
Total dividends collected$1.4K$21.0K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusBuyBuy
Analyst price target$252.33$428.67

Year-by-year: CAH vs SYK ($10,000, DRIP)

YearCAH PortfolioCAH Income/yrSYK PortfolioSYK Income/yrGap
1← crossover$10,804$104.30$10,852$152.43$48.00SYK
2$11,672$111.21$11,838$226.03$166.00SYK
3$12,607$118.57$13,004$336.89$397.00SYK
4$13,616$126.40$14,420$505.63$804.00SYK
5$14,704$134.73$16,195$766.09$1.5KSYK
6$15,877$143.59$18,504$1,175.64$2.6KSYK
7$17,142$153.02$21,635$1,835.40$4.5KSYK
8$18,504$163.04$26,082$2,932.10$7.6KSYK
9$19,973$173.70$32,737$4,829.68$12.8KSYK
10$21,557$185.04$43,312$8,282.98$21.8KSYK

CAH vs SYK: Complete Analysis 2026

CAHHealthcare

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Full CAH Calculator →

SYKHealthcare

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Full SYK Calculator →
📬

Get this CAH vs SYK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAH vs SCHDCAH vs JEPICAH vs OCAH vs KOCAH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.